Biological Dynamics' ExoVita Pancreas

Feb 10, 2023

Biological Dynamics said this week that it has validated and launched a laboratory-developed test, ExoVita Pancreas, through the company's CLIA-certified and CAP-accredited lab. The firm's assay platform involves isolation of exosomes with particular protein biomarkers from a standard blood sample, in this case to detect stage 1 and stage 2 pancreatic ductal adenoma carcinomas.

Biological Dynamics said that it intends to further validate the assay in a trial called ExoLuminate, which is currently enrolling patients with a high risk for pancreatic cancer. Eligible patients include those with a known familial or genetic predisposition, or certain clinical symptoms.

Biological Dynamics' ExoVita Pancreas

Cerebral Palsy Sequencing Study Finds Clinically Actionable Alterations

Lucid Diagnostics Raises $22M in Convertible Debt Refinancing

Medicover Genetics Receives IVDR Certification for Genetic Testing Reagent Kit

Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint

Multi-Ancestry Study Uncovers Genetic Contributors to Progressive Eye Disease